ライフサイエンスコーパス: pentostatin

1 ts (25%) had toxicity requiring them to stop pentostatin.

2 (MMF), denileukin diftitox (denileukin), or pentostatin.

3 steroid taper was begun after three doses of pentostatin.

4 ine, 3 underwent splenectomy, and 1 received pentostatin.

5 ntial for inappropriate immunosuppression by pentostatin.

6 r were decreased in septic mice treated with pentostatin.

7 ly improved at 48 hours in mice treated with pentostatin.

8 ly attenuated in septic animals treated with pentostatin (0.42 +/- 0.05 versus 0.21 +/- 0.04; p < 0.0

9 re treated with six cycles of induction with pentostatin (2 mg/m(2) on day 1), cyclophosphamide (600

10 emia (CLL), we initiated a trial of combined pentostatin (2 mg/m2), cyclophosphamide (600 mg/m2), and

11 Pentostatin (2'-deoxycoformycin), an inhibitor of adenos

12 etanercept 26%, MMF 60%, denileukin 53%, and pentostatin 38%.

13 Pentostatin 4 mg/m(2) with cyclophosphamide 600 mg/m(2)

14 All patients received pentostatin 4 mg/m(2).

15 Patients received pentostatin 4 mg/m2 intravenously every 2 weeks for 12 d

16 Patients received pentostatin 4 mg/m2, cyclophosphamide 600 mg/m2, and rit

17 etanercept 48%, MMF 44%, denileukin 62%, and pentostatin 57%.

18 e agent (5) or combined with: rituximab (2), pentostatin (6), fludarabine, cyclophosphamide, and ritu

19 10(-13) M) (8R)-hydroxyl-2'-deoxycoformycin (pentostatin), a transition state analogue, and (6S)-hydr

20 Pentostatin, a potent inhibitor of adenosine deaminase,

21 Pentostatin, a potent inhibitor of adenosine deaminase,

22 nt 24 hrs in advance of the inciting insult, pentostatin also has the unique potential for use as a t

23 potential usefulness of 2'-deoxycoformycin (pentostatin), an inhibitor of adenosine deaminase, as a

24 Pentostatin, an adenosine deaminase inhibitor, leads to

25 Eight dogs were conditioned with 6x4 mg/m pentostatin and 100 cGy TBI, whereas two dogs received 3

26 t introduction of purine nucleoside analogs (pentostatin and cladribine) changed the natural history

27 The purine analogs, pentostatin and cladribine, induce high remission rates

28 We previously reported that pentostatin and cyclophosphamide (PC) is active and well

29 work has shown that SS1P in combination with pentostatin and cyclophosphamide can result in durable t

30 , sirolimus, mycofenolate mofetil, imatinib, pentostatin and infusion of mesenchymal stem cells have

31 l curves for patients initially treated with pentostatin and those crossed over were similar.

32 splenectomy, interferon alfa-2a and alfa-2b, pentostatin, and cladribine.

33 Of the purine analogs active in CLL, pentostatin appears to be the least myelosuppressive.

34 a randomized, intergroup study who received pentostatin as an initial treatment or who crossed over

35 Two hundred forty-one patients treated with pentostatin as initial therapy (n = 154) or who crossed

36 We hypothesized that addition of pentostatin before transplantation could, in part, subst

37 Pentostatin, cyclophosphamide, and rituximab (PCR) in CL

38 of these results, we are currently studying pentostatin, cyclophosphamide, and rituximab (PCR) thera

39 Thus, this novel regimen of pentostatin, cyclophosphamide, and rituximab for previou

40 f a phase 2 study evaluating the efficacy of pentostatin, cyclophosphamide, and rituximab in patients

41 to groups to receive saline, bortezomib, the pentostatin/cyclophosphamide (PC) regimen, or the bortez

42 Pentostatin, denileukin diftitox, mycophenolate mofetil,

43 Patients were randomly assigned to pentostatin doses of 0, 0.5, 1.0, 1.5, and 2.0 mg/m(2) w

44 Pentostatin doses of 1.0 and 1.5 mg/m(2) had the highest

45 In rats given pentostatin either 2 hrs after the insult, or 24 hrs bef

46 lant Consortium performed a phase 2 trial of pentostatin for steroid-refractory chronic GVHD in 51 ch

47 Of the 86 courses of pentostatin given, 39 were administered at doses of 5.0

48 Pentostatin has activity in patients with steroid-refrac

49 Pentostatin has activity in refractory chronic GVHD in c

50 Pentostatin has immunosuppressive effects that are curre

51 The nucleoside analogue, pentostatin, has demonstrated high complete response rat

52 We examined the toxicity and efficacy of pentostatin in a prospective phase II trial in corticost

53 Building on the prior work of use of pentostatin in chronic lymphocytic leukemia (CLL), we in

54 Herpes zoster was seen within 1 year after pentostatin in five patients (19%).

55 Pentostatin increased the likelihood of success as defin

56 Many treatments exist, including cladribine, pentostatin, interferon-alpha, splenectomy, rituximab (m

57 neal cecal slurry) were treated with 1 mg/kg pentostatin intraperitoneally 24 hrs before, or intraven

58 Pentostatin is a highly effective regimen for hairy cell

59 Pentostatin is an active agent in heavily pretreated T-c

60 The combination of alemtuzumab and pentostatin is feasible and effective in T-cell neoplasm

61 Of the purine analogs active in CLL, pentostatin may be least myelosuppressive.

62 therapy with intravenous alemtuzumab and/or pentostatin, median progression-free survival and overal

63 with a variety of agents, including 30 with pentostatin; none achieved complete remission (CR).

64 cGy TBI, whereas two dogs received 3x4 mg/m pentostatin plus 100 cGy TBI.

65 though the nucleoside analogs cladribine and pentostatin produce high response rates in patients with

66 he kinetics of lymphodepletion and safety of pentostatin (PT) conditioning in alloNST.

67 e results of therapy with new agents such as pentostatin, pulse cyclophosphamide, long-wavelength ult

68 e nucleoside purine analogues cladribine and pentostatin results in lengthy remissions in nearly all

69 Treatment of septic mice with pentostatin significantly decreased leukocyte rolling an

70 Pharmacokinetic studies showed pentostatin significantly inhibited adenosine deaminase

71 onor lymphocyte infusion (DLI) alone or with pentostatin to convert to complete donor chimerism.

72 We hypothesized that addition of pentostatin to GVHD prophylaxis with tacrolimus and mini

73 These data indicate that the novel use of pentostatin to prevent systemic inflammatory response sy

74 tients with a confirmed complete response to pentostatin treatment, 5- and 10-year relapse-free survi

75 es to the septic challenge were abrogated by pentostatin treatment.

76 ignancies do not appear to be increased with pentostatin treatment.

77 Pentostatin was administered to 28 patients who had rela

78 me were abrogated and survival improved when pentostatin was not given until after signs of the illne

79 We hypothesized that combining pentostatin with cyclophosphamide would have less myelot